Recursion Pharmaceuticals RXRX announced a significant investment worth $50 million from NVIDIA Corporation NVDA, a renowned technology company specializing in accelerated computing. This investment ...

Recursion Pharmaceuticals (RXRX) closed the latest trading day at $5.41, indicating a -1.64% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Technology from computing powerhouse Nvidia is already hard at work inside companies at the convergence of technology and biology, including the supercomputer driving Recursion Pharmaceutical’s drug ...

Recursion hopes to transform the healthcare industry with its innovative drug discovery platform. The small company has gained the interest of Nvidia, which has invested in the business. Together, the ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...

Recursion Pharmaceuticals RXRX shares have gained 5.5% in a month. The stock gained momentum after the company announced the acquisition of Rallybio’s full stake in their joint venture earlier this ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

We recently published 10 Best Biotech Stocks to Buy Under $10. Recursion Pharmaceuticals, Inc. is placed eighth among them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage ...